Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone.
bone density
bone turnover
diabetes
osteocalcin
testosterone
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Aug 2019
01 Aug 2019
Historique:
received:
03
01
2019
accepted:
25
06
2019
entrez:
13
8
2019
pubmed:
14
8
2019
medline:
14
8
2019
Statut:
epublish
Résumé
One-third of men with type 2 diabetes have subnormal free testosterone concentrations. We evaluated the following: (i) whether bone mineral density (BMD) and bone strength are affected by gonadal status in type 2 diabetes and (ii) the effect of testosterone replacement on markers of osteoblast and osteoclast activity. This is a Men with subnormal free testosterone had similar BMD compared with men with normal free testosterone. However, bone strength indices were lower in men with subnormal free testosterone. BMD was related to free estradiol concentrations (r = 0.37, We conclude that testosterone replacement resulted in an increase in osteocalcin and a transient increase in CTx, indicating an increase in osteoblastic activity and transient increase in bone breakdown. Therefore, a major action of testosterone is to increase bone turnover in men with type 2 diabetes.
Identifiants
pubmed: 31403089
doi: 10.1210/js.2018-00426
pii: 201800426
pmc: PMC6682410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1617-1630Références
Clin Endocrinol (Oxf). 2001 Jun;54(6):739-50
pubmed: 11422108
J Bone Miner Res. 2004 Jul;19(7):1084-91
pubmed: 15176990
J Bone Miner Res. 2005 Jun;20(6):962-70
pubmed: 15883636
J Bone Miner Res. 2005 Aug;20(8):1334-41
pubmed: 16007330
J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7
pubmed: 16189261
Eur J Radiol. 2006 Jun;58(3):431-4
pubmed: 16513312
J Urol. 2006 May;175(5):1679-83; discussion 1683
pubmed: 16600728
Am J Med. 2006 May;119(5):426-33
pubmed: 16651055
Diabetes Care. 2007 Jul;30(7):1860-1
pubmed: 17416787
Am J Epidemiol. 2007 Sep 1;166(5):495-505
pubmed: 17575306
J Bone Miner Res. 2008 May;23(5):705-14
pubmed: 18086006
J Clin Endocrinol Metab. 2009 Mar;94(3):853-60
pubmed: 19106273
J Clin Endocrinol Metab. 2009 Sep;94(9):3337-46
pubmed: 19584177
J Clin Endocrinol Metab. 2009 Dec;94(12):4785-92
pubmed: 19820017
Steroids. 2010 Feb;75(2):169-75
pubmed: 19925815
Mol Hum Reprod. 2010 Jun;16(6):402-10
pubmed: 20348548
J Bone Miner Res. 2011 Jan;26(1):27-34
pubmed: 20499362
J Clin Endocrinol Metab. 2010 Sep;95(9):4314-23
pubmed: 20554716
Arch Biochem Biophys. 2010 Nov 1;503(1):118-28
pubmed: 20637179
Diabetes Care. 2011 Aug;34(8):1854-9
pubmed: 21715518
Trends Endocrinol Metab. 2012 Nov;23(11):576-81
pubmed: 22595550
J Clin Endocrinol Metab. 2012 Sep;97(9):3240-50
pubmed: 22740707
J Clin Endocrinol Metab. 2012 Oct;97(10):3744-50
pubmed: 22855334
Indian J Endocrinol Metab. 2012 Nov;16(6):947-51
pubmed: 23226640
J Bone Miner Res. 2014 Apr;29(4):787-95
pubmed: 24123088
Osteoporos Int. 2014 Jun;25(6):1697-708
pubmed: 24676844
J Bone Miner Res. 2014 Nov;29(11):2474-82
pubmed: 24806509
Diabetologia. 2014 Oct;57(10):2057-65
pubmed: 24908567
Lancet. 2015 Sep 19;386(9999):1147-55
pubmed: 26144908
Diabetes Care. 2016 Jan;39(1):82-91
pubmed: 26622051
J Clin Invest. 2016 Mar 1;126(3):1114-25
pubmed: 26901812
JAMA Intern Med. 2017 Apr 1;177(4):471-479
pubmed: 28241231
Sci Rep. 2018 Jun 14;8(1):9099
pubmed: 29904126
Diabetes Care. 2018 Jul;41(7):1516-1525
pubmed: 29934480
Clin Endocrinol (Oxf). 1988 Oct;29(4):437-41
pubmed: 3266960
Ann Intern Med. 1987 Mar;106(3):354-61
pubmed: 3544993
Endocr Rev. 1995 Feb;16(1):87-116
pubmed: 7758434
J Am Geriatr Soc. 1993 Feb;41(2):149-52
pubmed: 8426037
J Clin Endocrinol Metab. 1996 Oct;81(10):3654-62
pubmed: 8855818
J Clin Endocrinol Metab. 1997 Aug;82(8):2386-90
pubmed: 9253305
Lancet. 1997 Aug 23;350(9077):550-5
pubmed: 9284777
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
pubmed: 9661593